Ranbaxy, AstraZeneca settle over Nexium
On April 14, 2008, AstraZeneca announced a settlement with Ranbaxy over the Hatch-Waxman litigation concerning Nexium.
The WSJ reported:
The settlement means that Ranbaxy will be able to begin selling a generic version of Nexium from May 27, 2014. "Under the settlement agreement, Ranbaxy concedes that all six patents asserted by AstraZeneca in the patent litigation are valid and enforceable," said AstraZeneca in a statement. "Ranbaxy also accepts that four of the patents would be infringed by the unlicensed sale of Ranbaxy's proposed generic product."
The WSJ reported:
The settlement means that Ranbaxy will be able to begin selling a generic version of Nexium from May 27, 2014. "Under the settlement agreement, Ranbaxy concedes that all six patents asserted by AstraZeneca in the patent litigation are valid and enforceable," said AstraZeneca in a statement. "Ranbaxy also accepts that four of the patents would be infringed by the unlicensed sale of Ranbaxy's proposed generic product."
posted by Lawrence B. Ebert at 4:22 AM
0 Comments:
Post a Comment
<< Home